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Abstract
Aims: Depression is commonly observed even in prodromal stages of Lewy body 
disorders (LBD), and is associated with cognitive impairment and a faster rate of 
cognitive decline. Given the role of dopamine in the development of movement 
disorders, but also in motivation and reward, we investigated neurodegenerative 
pathology in dopaminergic circuitry in Parkinson’s disease (PD), PD with dementia 
(PDD) and dementia with Lewy bodies (DLB) patients in relation to depressive 
symptoms.
Methods: α-synuclein, hyperphosphorylated tau and amyloid-beta pathology was 
assessed in 17 DLB, 14 PDD and 8 PD cases within striatal and midbrain subre-
gions, with neuronal cell density assessed in substantia nigra and ventral tegmental 
area. Additionally, we used a structural equation modeling (SEM) approach to 
investigate the extent to which brain connectivity might influence the deposition of 
pathological proteins within dopaminergic pathways.
Results: A significantly higher α-synuclein burden was observed in the substantia 
nigra (P  =  0.006), ventral tegmental area (P  =  0.011) and nucleus accumbens 
(P  =  0.031) in LBD patients with depression. Significant negative correlations were 
observed between cell density in substantia nigra with Lewy body (LB) Braak stage 
(P  =  0.013), whereas cell density in ventral tegmental area showed negative correla-
tions with LB Braak stage (P  =  0.026) and neurofibrillary tangle Braak stage 
(P  =  0.007).
Conclusions: Dopaminergic α-synuclein pathology appears to drive depression. Selec-
tive targeting of dopaminergic pathways may therefore provide symptomatic relief 
for depressive symptoms in LBD patients.
INTRODUCTION
Parkinson’s disease (PD), PD with dementia (PDD) and 
dementia with Lewy bodies (DLB) are the most common 
Lewy body disorders (LBD) (91), sharing many clinical and 
pathological characteristics (59, 60). LBD are pathologically 
characterized by abnormal aggregation of misfolded α-synuclein 
(α-syn) protein, which is the major component of Lewy bodies 
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(LB) and Lewy neurites (LN) (14, 58), the distribution of 
which is associated with motor and cognitive changes. 
Comorbid Alzheimer’s disease (AD) pathology is commonly 
observed, particularly in DLB, in the form of extracellular 
amyloid plaques, of amyloid-beta (Aβ) peptide, along with 
neurofibrillary tangles (NFT) and neuropil threads of hyper-
phosphorylated tau (HPT) protein (42).
The prevalence of neuropsychiatric symptoms in LBD 
is high (77, 81, 102), with depression being the most com-
mon prodromal psychiatric symptom in LBD patients, 
often preceding the onset of motor symptoms (57, 76, 88). 
Depression is also associated with cognitive impairment 
(29, 103) and faster rate of cognitive decline in LBD 
(12, 28). Monoaminergic deficits in depression are well-
established, such as serotonin (5-HT), norepinephrine (NE) 
and dopamine (92). PD patients with depression show 
increased serotonin transporter binding in raphe and limbic 
regions (75), whereas decreased 5-HT1A receptor densities 
in limbic regions including insula, hippocampus and orbito-
frontal cortex are seen (6). Selective serotonin reuptake 
inhibitors (SSRI) are the most commonly prescribed anti-
depressants in PD patients with depression, although their 
efficacy in treating depression in PD is not supported by 
placebo controlled clinical trials (90). In PD, there are 
noradrenergic deficits due to loss of neurons in the locus 
coeruleus (LC), with reductions in noradrenaline found 
in caudate, putamen and cortical regions (33, 34). These 
changes are suggested to be related to the presence of 
depression as an early indication of LBD, since staging 
of pathology suggests degeneration of the LC before SN 
degeneration (96). Some studies have shown a marked 
reduction in 5-HT and NE levels in striatal, cortical and 
hippocampal regions in AD patients with depression (7, 
17, 97, 98), indicating that deficits in these neurotransmit-
ters may relate to depression in AD. The differences between 
depression in LBD and AD may lie in the neural 
substrates, with dopamine metabolism being the major 
neurochemical difference.
Dopamine deficiency in the nigrostriatal dopamine path-
way caused by progressive α-syn associated neurodegenera-
tion and loss of dopaminergic neurons in the substantia 
nigra (SN) pars compacta results in dopamine depletion 
in the dorsal striatum and the development of motor 
symptoms in LBD (69). The mesolimbic dopamine pathway 
sends dopaminergic projections from the ventral tegmental 
area (VTA) within the midbrain to various cortical and 
subcortical regions including the nucleus accumbens (NAcc) 
in the ventral striatum. Consequently, the VTA plays a 
role in pathophysiology of mood disorders and cognitive 
deficits (18, 36, 63, 82, 86). The extensive interconnections 
of the insular cortex with basal ganglia and limbic system, 
also makes it a key integrator of cognitive and emotional 
processing (11, 32). Since anhedonia and loss of motivation 
are core symptoms of depression it is likely that dysfunc-
tion of dopaminergic circuitry is involved in mediating 
depressive behaviors (16, 95).
Dopamine depletion is observed in L-dopa naïve PD 
and DLB cases, which correlates with reduction in atten-
tion and cognition (68, 70, 72), and this is likely to derive 
from changes to the dopaminergic VTA (74). Improved 
cognition and mood in PD is observed following L-dopa 
therapy (56) and correlates with a basal failure to inactivate 
the default mode network (22). Structural changes to basal 
ganglia circuitry in LBD are minimal (15) or absent (101) 
suggesting that changes within specific nuclei may be the 
major contributors of psychiatric symptoms (2, 15, 20, 46). 
Some studies have suggested an association of major depres-
sion with neuropathological processes in AD, with a higher 
Aβ plaque and NFT burden within the hippocampus and 
cortical regions in depressed individuals (64, 78). Therefore, 
depressive prodromal symptoms in LBD may be directly 
linked to neuropathological changes in the brain.
Neurodegeneration along specific pathways are the neu-
ropathological correlate of distinct clinical phenotypes 
and this is assumed to be due to prion-like spread of 
misfolded proteins (eg, α-syn and HPT) through anatomi-
cally interconnected brain regions (3, 21, 39, 53, 80, 89, 
100). Nigrostriatal degeneration occurs early in PD and 
PDD, where distribution and spreading of α-syn are closely 
correlated with clinical symptoms and disease progression, 
respectively (25, 89). Indeed, current pathological staging 
of LBD suggests spread of synuclein pathology from spe-
cific medullary nuclei to SN and then to allocortical and 
neocortical regions (14). Grafted fetal nigral neurons in 
PD patients show LB inclusions years after transplanta-
tion, suggesting that physical contacts between susceptible 
regions, axonal transport and trans-synaptic transmission 
of misfolded and aggregated α-syn might have a role in 
the pathogenesis and propagation of PD (48, 51). Therefore, 
specific clinical symptoms in LBD patients may be due 
to accumulation of misfolded proteins in different brain 
regions within specific anatomical pathways.
Since dopaminergic projections are involved in motor, 
cognitive and psychiatric deficits in LBD, changes in 
specific nuclei may relate to specific clinical symptoms. 
Therefore, we investigated how α-syn, Aβ and HPT pathol-
ogy affect nigrostriatal and mesolimbic dopaminergic 
circuitries in LBD in relation to depressive symptoms.
MATERIALS AND METHODS
Post-mortem tissue
All post-mortem human brain tissue was obtained from 
Newcastle Brain Tissue Resource (NBTR), with ethical 
approval for the study granted by the Newcastle and North 
Tyneside NHS Research Ethics Committee. All participants 
had received detailed clinical assessments during life and 
had consented to the donation and use of their brain tissue 
for research purposes. Post-mortem neuropathological assess-
ment was performed according to standardized neuropatho-
logical diagnostic procedures, which together with clinical 
data was used to make a clinicopathological diagnosis (59).
Three disease groups were included in this study, 17 
DLB, 14 PDD and 8 PD cases (supplementary Table S1). 
Of note, 4 DLB and 1 PDD case also fulfilled the neu-
ropathological criteria for high AD neuropathological 
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change (66) and can therefore be classified as neuro-
pathologically mixed AD/DLB with a LBD clinical phe-
notype (99). Case selection for neuropathological analysis 
was based on the availability of clinical data, with sequen-
tial scores of Mini-Mental State Examination (MMSE), 
the Unified Parkinson’s Disease Rating Scale (UPDRS), 
as well as neuropsychiatric information. The clinical 
diagnosis of depression was made by consulting psychia-
trist (supplementary Table S1). The inclusion criteria for 
depression diagnosis was made using the Cornell Scale 
for Depression in Dementia (CSDD) (≥8), as a validated 
rating scale for depression in dementia (5), or the Geriatric 
Depression Scale (GDS) (≥10), whiles less sensitive, shown 
to retain acceptable qualities when applied to a popula-
tion of demented elderly patients (49). In the absence of 
clinical diagnosis of depression by a consulting psychia-
trist, we used retrospective analysis of clinical records 
to verify the presence or absence of depression.
Sample preparation
At autopsy, the brain weight and post-mortem delay were 
recorded. The right hemisphere was fixed in 10% formalin. 
Following fixation, the hemisphere was cut into 7mm 
coronal slices then dissected into blocks and embedded 
in paraffin wax for neuropathological assessment. Paraffin 
embedded blocks selected for analysis corresponded to 
striatal and midbrain subregions, including the NAcc, 
caudate nucleus, anterior and posterior putamen, globus 
pallidus internus and externus, insula cortex, as well as 
SN and VTA at the level of the red nucleus. Six microm-
eter sections were immunostained with primary antibodies 
to α-syn, HPT and Aβ following antigen retrieval according 
to optimized protocols (supplementary Table S3) (99). The 
midbrain sections were stained with Cresyl fast violet to 
assess cell density, with the images captured using 63x oil 
immersion. A modified stereological method was employed 
to determine the neuronal cell density (67), with values 
calculated as cells per mm2.
Neuropathological assessment
For quantification of neuropathological lesions, section images 
were captured using a Zeiss Z1 microscope and MRc camera 
(Zeiss, Germany) coupled to a PC. The images were sampled 
using stereological methods, with the region of interest drawn 
at 1.25× magnification. Dissector boxes were placed in a 
uniform and unbiased way within the region of interest 
using stereology software (Stereologer, Chester, MD, USA), 
with 10–15 frames captured at 10× magnification per region 
of interest for densitometric analysis. The images were ana-
lyzed using Fiji Image J analysis software (Windows 64-bit: 
https://fiji.sc) (87). The mean percentage area stained for 
each frame was determined using the Red-Green-Blue (RGB) 
thresholds, which were adjusted manually for each antibody 
to eliminate the detection of non-specific staining. The mean 
percentage area stained per case in all the regions was cal-
culated from the mean values obtained across all images 
taken (99).
Statistical analysis
Statistical analysis was undertaken in SPSS Statistics ver-
sion 23.0 and in R. Assuming normally distributed data 
and equal group sizes (n  =  15 with/without depression) 
and 20% standard deviation of the mean of a specific 
measure, the study was powered (β  =  0.8 at α  =  0.05) 
to detect an effect size of 0.21. Distributional assumptions 
for outcome measures were assessed using the Shapiro–
Wilk test. As the neuropathological data was not normally 
distributed, we used non-parametric Mann–Whitney test 
for comparison of two groups and Kruskal–Wallis test 
for multiple groups. Trends in MMSE and UPDRS through 
time for different disease groups were investigated using 
linear mixed effect modeling. These models were fitted 
individually for MMSE and UPDRS measures in the nlme 
package in R. Cohen’s effect (d′) was calculated as an 
estimate of change of rate in MMSE and UPDRS scores 
(10). Correlation analyses were carried out using Spearman’s 
correlation coefficient ρ (rho). A canonical correspondence 
analysis was used to investigate the impacts of pathology, 
age, Braak NFT stage (13) and disease groups on the 
levels of protein deposition measured across all patients. 
This model was undertaken in the vegan package in R. 
We then created a conceptual model of the network of 
physical connectivity between different brain regions and 
investigated how levels of protein deposition were related 
across the connectivity network using Structural Equation 
Modeling (SEM). Since only 39 patients were available 
we used a Bayesian approach to investigate the extent of 
the connectivity network of protein deposition. The models 
were fitted in the Jags package in R.
RESULTS
Demographics
A total of 39 cases were included in this study for the 
neuropathological assessment. No significant difference was 
found in the age (P = 0.101) or post-mortem delay (P = 0.784) 
between different disease groups. The decline in MMSE 
scores with time was slower in PD patients compared to 
PDD and DLB (t  =  6.490, P  <  0.001), with no significant 
difference observed between PDD and DLB patients 
(t  =  0.619, P  =  0.54). There was no difference between 
UPDRS scores for PD and DLB (t  =  0.256, P  =  0.799), 
although scores were significantly higher in patients diag-
nosed with PDD (t  =  3.332, P  =  0.002) (supplementary 
Figure S1-S2). NFT Braak stage was not a significant 
predictor of MMSE (t  =  0.142, P  =  0.887) or UPDRS 
scores (t  =  0.480, P  =  0.635).
Clinical presentation
Within the cohort, 8 DLB, 9 PDD and 4 PD cases were 
diagnosed with depression. There was no significant dif-
ference in the age (P  =  0.754), post-mortem delay 
(P  =  0.987), NFT Braak stage (P  =  0.526) or LB Braak 
stage (P  =  0.315) in cases with and without depression. 
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LBD cases with and without depression also showed no 
differences in baseline (P  =  0.272) or last (P  =  0.688) 
MMSE scores, as well as baseline (P  =  0.167) or last 
(P = 0.273) UPDRS scores. Sixty six percent of LBD cases 
with depression were using SSRI, 9% SNRI and 24% TCA/
TeCA antidepressant medication.
Neuropathology
In general, PDD cases showed highest α-syn burden 
across the regions of interest, with moderate to severe 
α-syn pathology (LN and LB) observed in insula, SN, VTA 
and putamen (Figure 1). Alpha-synuclein burden was 
Figure 1. α-synuclein pathology distribution. Photomicrographs of 
α-synuclein pathology distribution in substantia nigra (SN), ventral 
tegmental area (VTA), putamen and insula in DLB (case #4, LB Braak 
stage 6), PDD (case #26, LB Braak stage 6) and PD (case #34, LB Braak 
stage 4). α-synuclein immunohistochemistry with KM51 antibody, ×20. 
Scale bar 300 µm.
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significantly different in caudate (H(2)  =  2.368, P  =  0.046), 
anterior putamen (H(2)  =  6.539, P  =  0.038) and insula 
(H(2)  =  8.391, P  =  0.015) across disease groups. Paired 
comparison between groups showed higher α-syn immu-
noreactivity in DLB cases compared to PD in anterior 
putamen (H(2) = 11.728, P = 0.041) and insula (H(2) = 13.383, 
P  =  0.014). No significant difference was observed in α-syn 
burden between DLB and PDD in midbrain and striatal 
subregions (Figure 2).
DLB cases showed highest HPT burden across all regions 
(Figure 3). HPT burden was significantly different across 
disease groups in SN (H(2)  =  10.374, P  =  0.006), VTA 
(H(2)  =  8.557, P  =  0.014) and insula (H(2)  =  11.080, 
P  =  0.004). Paired analysis showed higher HPT burden 
in DLB compared to PDD cases in SN (H(2)  =  13.055, 
P  =  0.005), VTA (H(2)  =  12.029, P  =  0.010) and insula 
(H(2)  =  10.576, P  =  0.031), as well as in DLB compared 
to PD in insula (H(2)  =  15.092, P  =  0.006). No significant 
difference was observed in HPT burden between disease 
groups in any striatal or pallidal subregion (Figure 4).
Diffuse Aβ plaques were observed in insula and puta-
men in DLB and PDD cases, whereas sparse Aβ deposits 
in SN and VTA (Figure 5). Aβ burden was significantly 
different in NAcc (H(2)  =  7.890, P  =  0.019), caudate 
(H(2)  =  8.775, P  =  0.012), anterior putamen (H(2)  =  6.533, 
P  =  0.038), posterior putamen (H(2)  =  13.814, P  =  0.001) 
and insula (H(2)  =  9.876, P  =  0.007) between disease 
groups. Paired analysis showed higher Aβ burden in DLB 
compared to PD in NAcc (H(2)  =  11.143, P  =  0.045), cau-
date (H(2)  =  11.375, P  =  0.030), posterior putamen 
(H(2)  =  17.312, p  =  0.001) and insula (H(2)  =  14.368, 
P  =  0.010) (Figure 6). No significant differences were 
observed in Aβ burden between DLB and PDD in mid-
brain or pallidal subregions.
Pigmented dopaminergic neurons were counted in SN 
and VTA, with means taken across the groups, generating 
(cells/mm2) values. Neuronal count in SN was significantly 
higher in controls compared to DLB (H(3)  =  20.25, 
P  =  0.001), PDD (H(3)  =  32.0, P  <  0.001) and PD 
(H(3)  =  19.21, P  =  0.028). Neuronal density in VTA was 
significantly higher in controls compared to DLB 
(H(3) = 22.18, P < 0.001) and PDD (H(3) = 22.16, P < 0.001), 
with no significant difference observed between controls 
and PD (Figure 7), although a mean reduction of around 
20% was observed. Cell density in SN showed significant 
negative correlation with LB Braak stage (r  =  −0.415, 
P  =  0.013), whereas cell density in VTA showed negative 
correlations with LB Braak stage (r  =  −0.360, P  =  0.026) 
and NFT Braak stage (r  =  −0.429, P  =  0.007).
Clinical and pathological correlates
The rate of change in MMSE scores in LBD cases showed 
significant negative correlations with α-syn burden in ante-
rior putamen (r  =  −0.329, P  =  0.046), insula (r  =  −0.455, 
P  =  0.008) and LB Braak stage (r  =  −0.384, P  =  0.025). 
Negative correlations were also observed between cognitive 
decline and tau pathology in anterior putamen (r = −0.455, 
P = 0.008), insula (r = −0.503, P = 0.002) and NFT Braak 
stage (r  =  −0.370, P  =  0.031), whereas Aβ burden with 
NAcc (r  =  −0.428, P  =  0.018), caudate (r  =  −0.399, 
P  =  0.017), anterior putamen (r  =  −0.420, P  =  0.011), 
posterior putamen (r  =  −0.408, P  =  0.018) and insula 
(r  =  −0.411, P  =  0.019). No correlations were observed 
between pathological burden and UPDRS rate of change.
LBD cases diagnosed with depression during life showed 
significantly higher α-syn burden in SN (U  =  2.719, 
P = 0.006), VTA (U = 2.521, P = 0.011) and NAcc (U = 2.155, 
P  =  0.031; Figure 8), whereas no significant differences 
were observed between LBD cases with depression and 
pathological burden of HPT and Aβ in striatal or midbrain 
subregions.
Canonical correspondence analysis
Canonical correspondence analysis was used to explore 
relationships between pathological protein burden across 
brain regions in relation to age, NFT Braak stage and 
disease group. The major trend (ie, Axis 1) was related 
to high levels of tau proteins (negative Axis 1) through 
to high levels of α-syn (high positive axis 1). The dis-
orders clearly separated PDD (with high α-syn deposition) 
on the positive side and DLB and PD to the negative 
side. PD cases were more associated with negative scores 
on the second axis. Age and Braak NFT stage were 
also negatively associated with the first axis indicating 
that older patients tended to be found with higher levels 
of HPT protein deposition, indicative of the separation 
of DLB and PDD (Figure 9). Since different parts of 
the brain are interconnected, it is likely that the 
Figure 2. Levels of α-synuclein pathology in LBD. α-synuclein pathology 
(% area stained) was assessed in substantia nigra (SN), ventral 
tegmental area (VTA), nucleus accumbens (NAcc), caudate (Cd), anterior 
and posterior putamen (Pu), globus pallidus internus (GPi) and externus 
(GPe) and insula between DLB, PDD and PD groups. *P < 0.05, DLB vs. 
PD.
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measures of the proteins in different brain region are 
not independent of each other. Therefore, it is likely 
that the presence of proteins in one compartment will 
be dependent on those in the brain to which they are 
directly connected.
Pathological spread modeling
We created a conceptual model of connectivity based on 
known major pathways of neuronal linkage between the 
regions being studied (supplementary Table S4), and 
employed measures of protein deposition in these areas 
Figure 3. Tau pathology distribution. Photomicrographs of tau 
pathology distribution in substantia nigra (SN), ventral tegmental area 
(VTA), putamen and insula in DLB (case #4, NFT Braak stage 6), PDD 
(case #26, NFT Braak stage 6) and PD (case #34, NFT Braak stage 4). 
HPT immunohistochemistry with AT8 antibody, ×20. Scale bar 300 µm.
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as response variables in a SEM approach to investigate 
the extent to which brain connectivity might influence the 
deposition of pathological proteins and development of 
symptoms. Density plots for the coefficients for three models 
are shown in supplementary Figures S3-S5.
Significant linkages between brain regions were observed 
for each protein (Figure 10). For α-syn there were signifi-
cant associations between levels of protein in VTA with 
anterior caudate. For SN, linkages with posterior putamen 
and α-syn were seen. Anterior putamen with posterior 
putamen, as well as insula cortex with anterior putamen 
also showed linkage. Weaker association trending on sig-
nificance was observed between α-syn level in SN with 
nucleus accumbens. HPT burden in SN was strongly linked 
to HPT burden in the nucleus accumbens. The anterior 
putamen showed linkage with posterior putamen, while 
HPT burden in VTA showed strongest linkage with the 
anterior putamen. Weaker linkages trending on significance 
were observed between SN with anterior putamen, as well 
as VTA with nucleus accumbens. In the case of Aβ there 
were significant linkages between levels of protein in the 
insula with anterior putamen, as well as anterior putamen 
with posterior putamen. Weaker linkages trending on sig-
nificance for Aβ were observed in posterior putamen with 
globus pallidus internus, as well as globus pallidus internus 
with externus.
DISCUSSION
Depression in LBD is common (1, 8, 77), causing major 
loss in quality of life (61, 62), however, the underlying 
systems that contribute to depression are unclear. Given 
the success of dopamine therapy in PD in reducing 
depressive symptoms (30, 40, 84, 85, 105), identifying those 
systems that contribute to depression across the LBD 
spectrum may have similar therapeutic success. We there-
fore investigated dopaminergic system pathology in LBD 
in relation to depression.
Pathological burden of α-syn was significantly higher 
in dorsal striatum and insula in DLB compared to PD 
cases, consistent with other studies (37, 43, 45). LBD cases 
with depression showed significantly higher α-syn levels 
in SN, VTA and NAcc, suggesting that the levels of α-syn 
pathology may be one of the main factors driving these 
symptoms. An increase in subcortical and cortical LB 
pathology has been observed in major depressive disorder 
(41, 94), as well as in amygdala in AD cases with a his-
tory of depression (52). Alpha-synuclein interaction with 
dopamine metabolism (31) and transmission (73, 107) may 
have important implications not only in neuronal loss and 
motor symptoms (9, 71), but also through development of 
depressive symptoms in LBD. Dysfunction in striatal con-
nectivity with limbic and cortical areas is suggested to 
underpin many neuropsychiatric symptoms in LBD (44), 
supported by the strong interaction of mesolimbic circuits 
with emotional processing (54). Our finding of an associa-
tion between α-synuclein pathology and depression in LBD 
strongly implicates spread of pathology from mesolimbic 
and mesostriatal dopaminergic neurons, which is supported 
by our finding of associations of α-synuclein spread through 
SEM (Figure 6). Based on our conceptual model of pro-
gression of neurodegeneration within dopaminergic path-
ways, this continued progression of symptoms may be 
underpinned by the neuronal connectivity in the brain 
and the spread of specific pathologies. A significant rela-
tionship was observed for α-syn spread from VTA to 
caudate, SN to putamen, as well as spread from the insula 
cortex to putamen. This suggested spread of α-syn from 
brainstem to both motor and non-motor parts of the 
striatum may indicate that not only mesolimbic, but also 
nigrostriatal dopaminergic circuits are needed in depres-
sion (4, 27).
DLB cases had higher HPT pathological burden in all 
striatal subregions and insula compared to other groups, 
as well as significantly higher burden in VTA and SN 
compared to PDD. Other studies have demonstrated sig-
nificantly higher HPT burden within striatal regions in 
DLB compared to PDD, perhaps in line with a generally 
higher NFT Braak scores in DLB (38, 45). Some studies 
have shown an association between AD cases with a life-
time history of depression and higher burden of NFT 
pathology in hippocampus (78, 79), as well as a positive 
correlation between depressive states and density of neuritic 
plaques in patients with dementia (65). Other studies have 
however shown an association of depressive symptoms in 
AD to be independent of cortical and brainstem plaques 
and tangles (93, 104). In this study, we found no associa-
tion between depression and HPT pathological burden 
within nigrostriatal and mesolimbic dopaminergic pathways 
in LBD cases. HPT levels showed strong linkages from 
Figure 4. Levels of tau pathology in LBD. Tau pathology (% area 
stained) was assessed in substantia nigra (SN), ventral tegmental area 
(VTA), nucleus accumbens (NAcc), caudate (Cd), anterior and posterior 
putamen (Pu), globus pallidus internus (GPi) and externus (GPe) and 
insula between DLB, PDD and PD groups. *P < 0.05, DLB vs. PDD; 
**P < 0.01, DLB vs. PDD; ##P < 0.01, DLB vs. PD.
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both SN and VTA to dorsal and ventral striatum in rela-
tion to potential spread of pathology using SEM (Figure 
6), which may suggest that higher HPT burden within 
dopaminergic pathways contributes to faster cognitive 
decline.
In line with data from PiB imaging studies (35), we 
also observed higher striatal Aβ deposition in DLB cases 
compared to PDD and PD. Striatal Aβ burden is suggested 
to be a strong correlate of dementia in PD (47), with 
differences in striatal Aβ deposition contributing to the 
Figure 5. Amyloid-beta distribution. Photomicrographs of Aβ pathology distribution in substantia nigra (SN), ventral tegmental area (VTA), putamen 
and insula in DLB (case #4), PDD (case #26) and PD (case #34). Aβ immunohistochemistry with 4G8 antibody, ×20. Scale bar 300 µm.
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timing of dementia relative to parkinsonism in DLB and 
PDD (45), potentially as a consequence of developing AD 
pathology. In this study, no relationship was observed 
between Aβ burden in dopaminergic circuitry and depres-
sion. While the potential role of Aβ in the pathophysiology 
of depression is unclear, some studies have shown an 
increase in binding using PET imaging in cortical regions 
in late-life depression (50, 106), while others failed to 
associate PET amyloid burden with depressive symptoms 
(19, 24, 55). Aβ showed a different pattern of pathology 
spread, primarily driven by inputs from the insula to 
anterior putamen, and also spread from anterior putamen 
to posterior putamen, which may indicate more cortically 
driven spread of Aβ pathology linked to cognition.
Overall, we observed clear time trends in MMSE and 
UPDRS scores, which were independent of age at onset 
or death and may therefore represent the continuing dys-
function and potentially pathological spread of changes 
within the CNS in LBD. The trends in cognitive decline 
were similar in DLB and PDD patients, but slower in PD 
cases, while decline in motor function with time was much 
greater in PDD patients than in PD or DLB. Significant 
negative correlations were observed between HPT and Aβ 
burden in dopaminergic nuclei, as well as limbic brain 
regions in LDB cases with faster rate of cognitive decline, 
which may suggest that AD pathology plays an important 
role in cognitive dysfunction in LBD, and progression of 
AD pathology may therefore relate to progression of 
symptoms.
Figure 6. Amyloid-beta pathology in LBD. Aβ pathology (% area 
stained) was assessed in substantia nigra (SN), ventral tegmental area 
(VTA), nucleus accumbens (NAcc), caudate (Cd), anterior and posterior 
putamen (Pu), globus pallidus internus (GPi) and externus (GPe) and 
insula between DLB, PDD and PD groups. *P  <  0.05, DLB vs. PD; 
**P < 0.01, DLB vs. PD; ***P < 0.001, DLB vs. PD.
Figure 7. Dopaminergic cell loss in the midbrain in LBD. Pigmented 
dopaminergic neuron counts in substantia nigra (SN) and ventral 
tegmental area (VTA) (cells/mm2) in controls, DLB, PDD and PD cases. 
*P < 0.05, controls vs. PD; **P < 0.01, controls vs. DLB; ***P < 0.001, 
controls vs. PDD; ###P < 0.001, controls vs. DLB and controls vs. PDD.
Figure 8. α-synuclein burden in depressed vs. non-depressed LBD cases. Significant pathological changes (% area stained) in depressed vs. 
nondepressed LBD cases. Significance levels set at *P < 0.05, **P < 0.01 and ***P < 0.001.
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Previous studies have shown α-syn pathological burden 
to be associated with nigral neuronal loss (23, 26, 83). In 
this study, neuronal loss in SN was greater with longer 
disease duration and a higher LB Braak stage, which may 
explain more severe neuronal loss in PDD cases. A higher 
burden of coexisting α-syn and AD type pathology in 
DLB and PDD cases may suggest increased neuronal vul-
nerability in the VTA.
These findings highlight the interaction between different 
types of pathology, which differentially affect brain struc-
tures within dopaminergic pathways, giving rise to certain 
clinical phenotypes. Dopaminergic α-syn pathology appears 
to drive depression, therefore, targeting these specific path-
ways and mechanisms may provide relief from depressive 
symptoms in LBD patients.
All the cases in this study were well clinically char-
acterized, with detailed neuropsychiatric information, as 
well as baseline and follow-up motor and cognitive assess-
ments. There are however, certain caveats to the study 
findings. While the prevalence of other psychiatric symp-
toms, such as visual hallucinations and REM sleep dis-
order, were not significantly different between depressed 
and non-depressed cases due to the high prevalence of 
these symptoms in the study group, 33% of depressed 
patients also had concomitant anxiety symptoms 
(χ2  =  0.056), which may need to be taken into account 
in future larger studies. Further, the classification of 
major depressive disorder was performed using a number 
of available sources. Although ideally cases would have 
been defined using a unified clinical score for depression 
in our LBD cohort, the different measures still have 
suitability for detecting depression in older populations. 
Our study has naturally focused on the dopaminergic 
system in LBD and the results suggest dopaminergic 
changes are a driver of depression in LBD. However, 
given the relatively small number of cases in this study, 
replication will be necessary in larger studies, and we 
cannot rule out noradrenergic or serotonergic involve-
ment in the pathogenesis of depression in LBD.
Figure 9. Canonical correspondence analysis. Pathological protein 
burden across brain regions in relation to age, Braak NFT stage and 
disease group. Note, DLB is the reference in this plot against which PD 
and PDD are compared.
Figure 10. Modeling of pathology spread in LBD. Structural Equation 
Model suggesting significant spread along pathways between brain 
regions based on levels of protein deposition in each region. Arrows 
indicate significant linkages between brain regions for α-synuclein, tau 
and Aβ, where the levels of protein in one region (end of arrow) were 
significantly related to levels in the other region from which the arrow 
starts (in this case assumed to be source).
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Figure S1. Trends in MMES scores in DLB, PDD and PD 
patients through time.
Figure S2. Trends in UPDRS scores for DLB, PDD and PD 
patients through time.
Figure S3. Density plot for the SEM coefficients for the 
full model for deposition of α-synuclein. Distributions for 
the coefficients beta(2), beta(5), beta(6) and beta(8) do not 
include zero, suggesting significant pathways between the 
two brain compartments.
Figure S4. Density plot for the SEM coefficients for the 
full model for deposition of tau protein. Distributions for 
the coefficients beta(3), beta(8) and beta(9) do not include 
zero suggesting significant pathways between the two brain 
compartments.
Figure S5. Density plot for the SEM coefficients for the full 
model for deposition of amyloid beta. Distributions for the 
coefficients beta(5) and beta(8) suggesting significant path-
ways between the two brain compartments.
Table S1. Demographic and neuropathological character-
istics for post-mortem cohort. PM delay refers to the time 
interval between death and fixation. McKeith criteria refers 
to Lewy body pathology. Braak stage, Braak NFT pathol-
ogy stage. CERAD, consortium to establish a registry of AD. 
MMSE - Mini-Mental State Examination. UPDRS - Unified 
Parkinson’s Disease Rating Scale.
Table S2. Clinical characteristics for post-mortem cohort. 
CSDD - Cornell Scale for Depression in Dementia; GDS - 
Geriatric Depression Scale; SNRI - Serotonin–norepineph-
rine reuptake inhibitor; SSRI - Selective serotonin reuptake 
inhibitor; TCA - Tricyclic antidepressant; TeCA - Tetracyclic 
antidepressant.
Table S3. Antibodies used for neuropathological analysis.
Table S4. Modeled links.
